The Filing Desk

Aquestive Therapeutics vs BGM Group

Aquestive Therapeutics AQST · BGM Group BGM · Pharmaceuticals

Aquestive Therapeutics reported revenue of $44 million in fiscal 2025, 1.2 times BGM Group's $38 million in fiscal 2025. Aquestive Therapeutics' revenue fell 22.6% in its latest year, and BGM Group's grew 51.1%. Aquestive Therapeutics had an operating margin of -159.5%, against -33.2% at BGM Group. Free cash flow was −$53 million at Aquestive Therapeutics and −$4 million at BGM Group. Their fiscal years end in different months (December 31 and September 30), so the periods don't line up exactly.

Side by side

Aquestive TherapeuticsBGM Group
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Sep 30, 2025
Revenue$44M$38M
Revenue growth−22.6%51.1%
Revenue growth a year, last 5 years−0.6%−5.4%
Gross margin58.4%16.6%
Operating margin−159.5%−33.2%
Net margin−188.1%−52.6%
Free cash flow−$53M−$4M
Free cash flow margin−119.0%−10.4%
Return on capital——
Net debt to EBITDA——
Dividends and buybacks$0M$0M
Change in diluted share count23.3%1,467.3%
Last close$3.71$8.00
P/E at the last close——
Insider trades, last 12 monthssold $2.3 million—
Piotroski F-score2 of 9—
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
Aquestive TherapeuticsBGM Group
Operating margin
Percent of revenue
Aquestive TherapeuticsBGM Group
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Aquestive TherapeuticsBGM Group

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Aquestive Therapeutics and BGM Group pages.